Information Provided By: 
Fly News Breaks for October 16, 2015
CEMP
Oct 16, 2015 | 12:41 EDT
Needham analyst Alan Carr says following Cempra's Phase 3 data this morning that his inclination is solithromycin will be approved in both the U.S. and Europe. The drug is likely to be an attractive option in community-acquired bacterial pneumonia, Carr tells investors in a research note. He keeps a Buy rating on Cempra with a $48 price target. The stock is down 30%, or $8.15, to $18.63 in midday trading.
News For CEMP From the Last 2 Days
There are no results for your query CEMP
